Malaysia MOH Reveals 77.88% of 2025 Drug Spending on Generics

In a recent statement, the Ministry of Health (MOH) of Malaysia has clarified its pharmaceutical procurement strategy for the year 2025, revealing that a significant portion of its budget, approximately RM3.01 billion, which is 77.88% of total spending, will be directed towards generic medicines. This announcement comes in the wake of claims from Pharmaniaga Bhd, which suggested that the government spent more on innovator drugs compared to generics, a statement that MOH has firmly rebutted.

The Ministry asserts that the total expenditure on medicines for 2025 amounts to RM3.86 billion, which encompasses various procurement methods including central contracts and direct purchases by healthcare facilities. Following the definitive breakdown provided, innovator drugs accounted for just RM850 million, or 22.12%, of the total spending. This shift towards generics signifies a growing trend toward cost-efficient health solutions within the Malaysian healthcare system.

MOH's reaffirmation of its preference for generic medicines is aligned with the National Medicines Policy (DUNas), which prioritizes these less costly alternatives over innovator drugs. Over the years, there has been a steady increase in expenditure on generics, which rose from 54.22% in 2021 to 77.88% in 2025. Such statistics not only demonstrate a clear commitment from MOH to fiscal responsibility but also showcase an intention to enhance access to essential medications for Malaysian citizens.

Furthermore, the MOH’s official statement indicated that the discrepancies in previously reported procurement figures could stem from varying data sources and an inaccurate interpretation of the procurement scope. They emphasize that accuracy in reporting is crucial, urging stakeholders to verify information before dissemination. The Ministry is dedicated to managing public resources wisely while ensuring a steady supply of quality and effective medications.

In light of these developments, pharmaceutical suppliers and contractors are advised to pivot their business strategies toward the generic segment of the Malaysian market. With an estimated 3,982 types of medicines procured, and generics comprising the majority, this represents significant contract opportunities for vendors adept in this area. Local manufacturers, in particular, are positioned favorably to benefit from MOH’s procurement policies which prioritize domestically produced medicines, reflecting a healthy environment for growth in Malaysia’s pharmaceutical industry.

As the market evolves and shifts toward generics, understanding the procurement landscape will be essential for businesses aiming to engage in Malaysian government contracts effectively. MOH's commitment to enhancing local industry capabilities in parallel with public health requirements ensures that upcoming bidding processes may reflect these priorities. This sets the stage for a competitive marketplace focused on providing the best possible outcomes for government procurement initiatives.